5857969
Last Update Posted: 2025-07-11
Recruiting
All Genders accepted | 1 Day-21 Years |
65 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.
Eligibility
Relevant conditions:
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Large Cell Lymphoma
Refractory Childhood Acute Lymphoblastic Leukemia
Refractory Childhood Hodgkin Lymphoma
Refractory Childhood Malignant Germ Cell Neoplasm
Recurrent Childhood Brain Tumor
Recurrent Childhood Brainstem Glioma
Recurrent Childhood Rhabdomyosarcoma
Recurrent Childhood Soft Tissue Sarcoma
Recurrent Childhood Ependymoma
Recurrent Childhood Lymphoblastic Lymphoma
Recurrent Childhood Gliosarcoma
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Childhood Malignant Solid Neoplasm
Recurrent Childhood Malignant Solid Neoplasm
Recurrent Childhood Malignant Neoplasm
Refractory Childhood Malignant Neoplasm
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov